COVID-19 vaccine design: the Janus face of immune enhancement

Peter J Hotez; David B Corry; Maria Elena Bottazzi

doi:10.1038/s41577-020-0323-4

COVID-19 vaccine design: the Janus face of immune enhancement

Nat Rev Immunol. 2020 Jun;20(6):347-348. doi: 10.1038/s41577-020-0323-4. Epub 2020 Apr 28.

Authors

Peter J Hotez^{1

2

3

4}, David B Corry^{5

6}, Maria Elena Bottazzi^{7

8

9}

Affiliations

¹ Texas Children's Center for Vaccine Development, Houston, TX, USA. hotez@bcm.edu.
² Departments of Pediatrics and Molecular Virology and Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA. hotez@bcm.edu.
³ Department of Biology, Baylor University, Waco, TX, USA. hotez@bcm.edu.
⁴ Hagler Institute for Advanced Study at Texas A&M University, College Station, TX, USA. hotez@bcm.edu.
⁵ Departments of Medicine (Immunology, Allergy and Rheumatology) and Pathology & Immunology, Baylor College of Medicine, Houston, TX, USA. dcorry@bcm.edu.
⁶ Michael E. DeBakey VA Center for Translational Research in Inflammatory Diseases, Houston, TX, USA. dcorry@bcm.edu.
⁷ Texas Children's Center for Vaccine Development, Houston, TX, USA. bottazzi@bcm.edu.
⁸ Departments of Pediatrics and Molecular Virology and Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA. bottazzi@bcm.edu.
⁹ Department of Biology, Baylor University, Waco, TX, USA. bottazzi@bcm.edu.

Abstract

Previous work on severe acute respiratory syndrome coronavirus (SARS-CoV) vaccines identified cellular immunopathology and antibody-dependent enhancement as potential safety issues. We discuss the implications of these findings for COVID-19 vaccine development and our approach to optimizing for safety and efficacy.

MeSH terms

Animals
Antibodies, Viral / immunology
Betacoronavirus / immunology
COVID-19
COVID-19 Testing
COVID-19 Vaccines
Clinical Laboratory Techniques
Clinical Trials as Topic
Coronavirus Infections / diagnosis
Coronavirus Infections / immunology*
Coronavirus Infections / prevention & control
Drug Design*
Humans
Pandemics / prevention & control
Pneumonia, Viral / immunology*
Pneumonia, Viral / prevention & control
SARS-CoV-2
Viral Vaccines* / immunology

Substances

Antibodies, Viral
COVID-19 Vaccines
Viral Vaccines